MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


IN BRIEF: NetScientific’s PDS suffers wider loss as R&D costs mount

ALN

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - Portfolio company PDS Biotechnology Corp reports results for the quarter to June 30. Net loss was $11.5 million, widened from $5.8 million the year before. Higher loss primarily due to costs incurred in connection with research and development programmes, which more than doubled to $8.0 million from $3.8 million. Loss per share of $0.37 compared to $0.20 before. Further, PDS reports the successful submission of final clinical protocol and supporting information to the US Food & Drug Administration to initiate phase 3 Versatile-003 trial in the fourth quarter. Adds biomarker data from Versatile-002 will be presented at the European Society for Medical Oncology Congress.

Current stock price: 62.20 pence

12-month change: down 5.0%

Copyright 2023 Alliance News Ltd. All Rights Reserved.